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ABSTRACT
Background: Clinical trials of immune checkpoints modulators, including both 
programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) 
inhibitors, have recently shown promising activity and tolerable toxicity in pre-treated 
NSCLC patients. However the predictive role of PD-L1 expression is still controversial. 
This pooled analysis aims to clarify the association of clinical objective responses 
to anti PD-1/PD-L1 monoclonal antibodies (MoAbs) and tumor PD-L1 expression in 
pre-treated NSCLC patients.
Methods: Data from published studies, that evaluated efficacy and safety of PD-1/
PD-L1 inhibitors in pre-treated NSCLC patients, stratified by tumor PD-L1 expression 
status (immunohistochemistry, cut-off point 1%), were collected by searching in 
PubMed, Cochrane Library, American Society of Clinical Oncology, European Society 
of Medical Oncology and World Conference of Lung Cancer, meeting proceedings. 
Pooled Odds ratio (OR) and 95% confidence intervals (95% CIs) were calculated for 
the Overall Response Rate (ORR) (as evaluated by Response Evaluation Criteria in 
Solid Tumors, version 1.1), according to PD-L1 expression status.
Results: A total of seven studies, with 914 patients, were eligible. Pooled analysis 
showed that patients with PD-L1 positive tumors (PD-L1 tumor cell staining ≥1%), 
had a significantly higher ORR, compared to patients with PD-L1 negative tumors 
(OR: 2.44; 95% CIs: 1.61-3.68).
Conclusions: PD-L1 tumor over-expression seems to be associated with higher 
clinical activity of anti PD-1/PD-L1 MoAbs, in pre-treated NSCLC patients, suggesting 
a potential role of PD-L1 expression, IHC cut-off point 1%, as predictive biomarker 
for the selection of patients to treat with immune-checkpoint inhibitors.
INTRODUCTION
Cancer immunotherapy is emerging as a very 
promising therapeutic strategy for several solid tumors, 
including non-small cell lung cancer (NSCLC). 
Differently from other treatment approaches directed 
against the tumor, such as chemotherapy or targeted 
therapy [1-6], targeting the immune system offers the 
potential for durable activity and long-term survival 
outcomes, regardless of tumor’s histological subtype or 
mutation status, with a unique, tolerable, toxicity profile. 
Among the different immunotherapeutic strategies 
under clinical investigation in NSCLC, the blockade 
of inhibitory immune-checkpoints with monoclonal 
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antibodies (MoAbs), is currently considered the most 
promising approach, promoting the immune-response 
against cancer cells [7-9]. Programmed cell death 
protein-1 (PD-1) is a checkpoint receptor expressed on 
the surface of activated T-cells, as well as on B-cells and 
natural killers (NK) [10], binding its natural ligands, 
PD-L1 and PD-L2, which may be expressed by both 
stromal and tumor cells [11]. The PD-1/PD-L1 axis is an 
inhibitory signaling pathway, causing T-cells exhaustion 
and inactivation, to prevent autoimmune response [11-
13]. However it represents also an important mechanism 
of immune-escape, co-opted by the tumor cells to limit 
T-cells activity in the tumor microenvironment during 
the late-stage of the “immune-editing process” [14]. An 
improved understanding of cancer immunology has led 
to the development of several MoAbs which are able to 
revert a non-efficient or suppressed immune-response by 
the blockade of the PD-1/PD-L1 axis [15, 16]. There are 
two different classes of MoAbs: the anti-PD-1 MoAbs, 
Nivolumab and Pembrolizumab are fully human and 
humanized, respectively, IgG4 MoAbs, blocking 
the binding between PD-1 receptor and its natural 
ligands, PD-L1 and PD-L2; the anti-PD-L1 MoAbs 
Atezolizumab, Durvalumab, and Avelumab are IgG1 
isotypes with genetically modified Fc fragments, which 
block the PD-L1 and prevent its interaction with PD-1 
receptor [17, 18]. All these MoAbs have shown a very 
promising activity in early phase I trials, reaching an 
overall response rates (ORR) of about 20%, in a heavily 
pre-treated and unselected NSCLC population [19-22]. 
Most of such responses occur relatively early, about 50% 
within eight weeks of treatment, and may be maintained 
for a long time [19]. These encouraging data have been 
recently confirmed by two prospective, randomized, 
phase III trials, comparing Nivolumab vs Docetaxel, in 
both squamous and non-squamous, advanced NSCLC, 
after prior chemotherapy-regimens failure [23, 24]. 
Even more exciting was the overall survival (OS) benefit 
obtained with Nivolumab in this setting of patients, 
leading to the approval of the first anti-PD-1 MoAb, by 
the Food and Drug Administration (FDA), for the second-
line treatment of squamous NSCLC. A relationship 
between PD-L1 expression on tumor cells and ORR has 
been first suggested by the phase I study of Topalian 
et al. [25]. In such study among 42 patients with different 
solid tumors evaluated with immunohistochemical 
analysis, none of those with PD-L1 negative tumor 
obtained an ORR, while about one third of patients with 
PD-L1 positive tumors had a clinical response. Since 
then, almost all clinical studies of immune-checkpoint 
inhibitors in NSCLC investigated the potential 
correlation between tumor PD-L1 expression and anti-
PD-1/PD-L1 MoAbs activity/efficacy [19-24, 26-30], 
in order to validate PD-L1 expression as predictive 
biomarker. The majority of such studies have shown that 
PD-L1 over-expression is associated with significantly 
higher ORR in pre-treated NSCLC population [19, 20, 
22, 24, 27-29], while some other studies have not found 
a significant association [21, 23, 26]. Although different 
immunohistochemistry (IHC) cut-off points, ranging 
from 1% to 50%, have been used to define the PD-L1 
positivity in tumor specimens, the results of the phase 
III CheckMate 057 study [24] have recently shown that 
PD-L1 (IHC, cut-off point 1%) significantly correlated 
with ORR, progression free survival (PFS) and overall 
survival (OS), in pre-treated NSCLC patients. These 
data suggested PD-L1 at the lowest expression level 
(IHC, cut-off point 1%) as the best cut-off, allowing to 
include all patients who may really benefit from these 
therapies. The aim of this pooled-analysis is to combine 
and analyze simultaneously all the studies reporting 
the ORR of pre-treated NSCLC patients receiving anti 
PD1/PD-L MoAbs, stratified according to the PD-L1 
expression status (IHC, cut-off point 1%), in order to 
provide a more precise estimation of the predictive role 
of PD-L1 expression in NSCLC.
RESULTS
Our search, according to the aforementioned 
criteria, performed in October 2015, identified 211 
publications. Among these, after a careful selection 
procedure, only seven studies (914 patients) met our 
inclusion criteria and were included in the pooled-
analysis (Figure 1) [20, 21, 23, 24, 26, 27, 30]. Three 
of these were early phase I studies, reporting the 
updated results of the immune-checkpoint inhibitors, 
Pembrolizumab [20], Atezolizumab [21], and Avelumab 
activity [30], in pre-treated NSCLC patient cohorts. In 
particular, the KEYNOTE-001 was a modern, large phase 
I study, including about 500 NSCLC patients treated with 
Pembrolizumab, which has shown an ORR of about 20% 
and an OS of about 12 months in the overall population, 
even higher among the patients with an increased tumor 
PD-L1 expression [20]. Two were phase II studies: a 
single arm trial of Nivolumab in patients with advanced 
refractory squamous NSCLC [26], and the randomized 
phase II trial comparing Atezolizumab vs docetaxel in 
287 pre-treated NSCLC patients, whose interim results 
have recently shown a significant benefit in favour of 
Atezolizumab, correlating with an increasing tumor PD-
L1 expression [27]. Two randomized, phase III studies, 
comparing Nivolumab vs docetaxel, in pre-treated, both 
squamous [23] and non-squamous [24] NSCLC patients, 
have both shown a significant improvement of the ORR 
and OS in the overall population treated with Nivolumab, 
reporting opposite results in the PD-L1 expression 
analysis. Indeed, the CheckMate 057 study demonstrated 
a strong predictive value of tumor PD-L1 expression 
in non-squamous NSCLC [24], while no significant 
association between Nivolumab benefit and PD-L1 
expression has been found in patients with squamous 
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histology in the CheckMate 017 trial [23]. In the included 
studies, sample sizes of the analyzed population ranged 
from 53 [21] to 231 [24], while the percentage of PD-
L1 positive tumors, IHC cut-off point 1%, ranged from 
50% [21] to 85% [20]. All these studies analyzed the 
ORR of pre-treated NSCLC patients stratified by tumor 
PD-L1 expression status (immunohistochemistry, cut-off 
point 1%). A detailed description of the selected studies 
is reported in the Table 1.
Pooled analysis showed that patients with PD-L1 
positive tumors (PD-L1 tumor cell staining ≥1%) had 
a significantly higher ORR compared to patients with 
PD-L1 negative tumors (OR: 2.44; 95% CIs: 1.61-3.68) 
(Figure 2). A significant difference in activity by PD-L1 
Figure 1: Flow-chart of studies selection
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status was confirmed for anti-PD1 MoAbs (OR: 2.62; 
95% CIs: 1.60-4.28) (Figure 3), with a no significant 
trend for anti-PD-L1 MoAbs (OR: 2.07; 95% CIs: 0.98-
4.38) (Figure 4). The pooled OR for ORR was calculated 
using fixed-effect model, because of non-significant 
heterogeneity between treatment effects (Q-test: P: 0.38). 
Publication bias have not been found either by Begg’s and 
Egger’s tests for ORR (P: 0.5 and P: 0.27, respectively), 
according to the PD-L1 expression status (Figure 5).
DISCUSSION
This pooled analysis included seven studies which 
evaluated the ORR of patients with NSCLC treated with 
anti PD1/PD-L1 MoAbs who received prior chemotherapy 
regimens stratified according to the tumor PD-L1 expression 
status (IHC, cut-off point 1%). The results of this work have 
shown that tumor PD-L1 positivity (PD-L1 tumor cell 
staining ≥1%) is associated with significantly higher ORR, 
suggesting a potential role of tumor PD-L1 over-expression 
as predictive biomarker for clinical setting. After the recent 
approval of Nivolumab by FDA for the second-line 
treatment of squamous NSCLC, searching for predictive 
biomarkers has become an urgent issue for clinical research. 
A validated biomarker would allow to select those patients 
who could benefit more from immune-therapies, sparing the 
others from ineffective high-cost treatments, as well as 
futile immune-related toxicities. In this scenario, tumor PD-
L1 expression represents the predictive biomarker most 
evaluated in clinical studies. Although the majority of such 
studies suggested a significant association between tumor 
PD-L1 expression and anti-PD-1/PD-L1 MoAbs activity 
[20, 24, 27], the two largest phase III randomized 
CheckMate 017 and 057 trials have shown opposite results. 
Indeed the CheckMate 017 study of Nivolumab in 
squamous NSCLC did not report any difference in terms of 
efficacy according to the tumor PD-L1 expression status 
[23], whereas the CheckMate 057 has recently shown that 
ORR nearly tripled and median OS nearly doubled with 
Nivolumab vs Docetaxel in pre-treated patients with PD-L1 
positive non-squamous NSCLC [24]. Such data suggested 
that PD-L1 has a predictive value limited to the 
adenocarcinoma, likely influencing also the results of our 
analysis. An individual patients data analysis by histology 
would be useful to determine if the predictive role of PD-L1 
expression in NSCLC is histology-driven, but unfortunately 
Table 1: Characteristics of the trials included in the pooled-analysis
Study 
(reference)
Drug Detection 
(cut-point)
ORR 
(PD-L1+) 
n.*(%)
ORR 
(PD-L1-) 
n.*(%)
PFS (PD-
L1+) m. 
(95% CI)
PFS (PD-
L1-) m. 
(95% CI)
OS (PD-
L1+) m. 
(95% CI)
OS (PD-
L1-) m. 
(95% CI)
Rizvi et al. 
2015 (phase II) 
(26)
Nivolumab IHC (1%) 9/45 (20) 4/31 (13) N.A N.A N.A N.A
Brahmer et al. 
2015 (phase 
III) (23)
Nivolumab IHC (1%) 11/63 (17) 9/54 (17) 3.3 3.1 9.3 8.7
Borghaei et al. 
2015 (phase 
III) (24)
Nivolumab IHC (1%) 38/123 (31) 10/108 (9) 4.2 2.1 17.2 9.4
Garon et al. 
2015 (phase I) 
(20)
Pembrolizumab IHC (1%) 37/134 (27) 2/22 (9) N.A N.A N.A N.A
Rizvi et al. 
2014 (phase I) 
(21)
Atezolizumab IHC (1%) 8/26 (31) 5/26 (20) N.A N.A N.A N.A
Spira et al. 
2015 (phase II) 
(27)
Atezolizumab IHC (1%) 17/93 (18) 4/51 (8) 3.3 1.9 N.A N.A
Gulley et al. 
2015 (phase I) 
(30)
Avelumab IHC (1%) 17/118 (14) 2/20 (10) 3 1.4 N.A N.A
ORR, Overall Response Rate; PD-L1; Programmed death-ligand 1; IHC, immunohistochemistry; n., number; m., months; 
N.A, not available.
*The number of patients reported corresponds to the number of patients evaluable
Oncotarget19742www.impactjournals.com/oncotarget
we didn’t have such informations. Another major issue 
emerging from the studies regards the heterogeneity of the 
IHC cut-offs, ranging from >1% to >50%, used to define the 
PD-L1 positivity in tumor specimens. Indeed PD-L1 has 
shown to be predictive of Nivolumab activity at different 
cut offs of 1%, 5% and 10% [24], while in the more recent 
KEYNOTE-001 trial of pembrolizumab in advanced 
NSCLC, patients’ survival significantly differed between 
patients with PD-L1 expression >50% in comparison with 
patients with a PD-L1 <50% [20]. The multitude of the 
detection methods by different PD-L1 IHC MoAbs used in 
the included studies, has further complicated the 
interpretation of the biomarker data analysis as well as their 
clinical applicability. The International Association for the 
Study of Lung Cancer (IASLC) Pathology Committee is 
currently working on this field in order to standardize and 
validate a reproducible IHC test for PD-L1 assessment [31]. 
According to the CheckMate 057 results [24], our work also 
demonstrated that tumor PD-L1 expression at the lowest 
IHC cut-off of 1%, significantly correlated with anti-PD-1/
Figure 2: Forest plot showing odds ratio for overall response rate to anti-PD-1/PD-L1 monoclonal antibodies according 
to the tumor PD-L1 expression status, in pre-treated NSCLC patients.
Figure 3: Forest plot showing odds ratio for overall response rate to anti-PD-1 monoclonal antibodies according to the 
tumor PD-L1 expression status, in pre-treated NSCLC patients.
Figure 4: Forest plot showing odds ratio for overall response rate to anti-PD-L1 monoclonal antibodies according to 
the tumor PD-L1 expression status, in pre-treated NSCLC patients.
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PD-L1 MoAbs activity in pre-treated NSCLC patients, 
confirming its potential role as predictive biomarker for 
clinical use. The non-significant trend observed for anti-
PD-L1 MoAbs is likely due to the lower number of patients 
included in the subgroup analysis. Similarly to other studies 
our work also demonstrated that more than 10% of PD-L1 
negative patients received also benefit by anti PD-1/ PD-L1 
therapies, suggesting that tumor PD-L1 expression could 
not be able to predict the overall immunotherapy benefit in 
NSCLC [32, 33]. Of course, the ORR (WHO, RECIST) 
may not be considered as the best endpoint to assess the 
predictive value of tumor PD-L1 expression. Differently 
from oncogene drivers, such as EGFR and EML4-ALK, 
which are associated with high response rates to targeted 
therapies (1-4), the predictive power of tumor PD-L1 
expression should be evaluated on the basis of long-term 
survival outcomes associated with these treatments. To date 
most of such outcomes are still immature, although 
preliminary OS for some of the anti-PD1/PD-L1 inhibitors 
seems to be associated with tumor PD-L1 status [20, 24]. A 
retrospective analysis presented at the last WCLC has 
shown that patients with NSCLC who achieved a best 
response (CR or PR) in the single arm study (CA209063) of 
Nivolumab had the longest survival, suggesting the ORR as 
a reliable surrogate endpoint of OS in patients receiving 
immunotherapy [34]. In addition patients whose best 
response was SD or PD according to RECIST and continued 
Nivolumab beyond PD had longer survival compared to 
patients with no treatment beyond PD [34]. Such findings 
suggested that traditional response criteria may not be able 
to fully capture the immune-therapy activity. Because of the 
retrospective nature of this analysis, such results should be 
interpreted cautiously and need to be confirmed by 
prospective studies. The immune-related response criteria 
(ir-RC) have shown to be more appropriate to capture the 
novel response patterns observed with immunotherapeutic 
agents and should be included in clinical trials investigating 
immunotherapies. Indeed according to the ir-RC the 
appearance of new lesions doesn’t necessarily identify a 
PD, because responses may occur also after a long time and/
or a conventional “RECIST” PD [35]. Another limitation of 
our analysis is represented by the heterogeneity of the 
selected studies, including four phase I-II single arm studies 
[20, 21, 26, 30] and three randomized phase II-III clinical 
trials [23, 24, 27], which investigated different anti-PD1/
PD-L1 MoAbs. However, all these MoAbs act on the same 
immune-modulating pathway, but especially the same study 
population. Indeed only studies reporting data dedicated to 
pre-treated NSCLC patients were included, in order to 
enhance the precision and the accuracy of the results. 
Figure 5: Funnel plot of odds ratio (OR) for response rate (RR) according to the PD-L1 expression status in pre-treated 
NSCLC patients receiving anti-PD-1/PD-L1 treatments. Each study is represented by one circle- the vertical line represents the 
pooled effect estimate.
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Finally the high PD-L1 expression heterogeneity in the 
tumor microenvironment could further reduce the potential 
role applicability of such predictive biomarker for clinical 
setting [36]. Indeed PD-L1 expression seems to be a 
dynamic biomarker, subjected to both space (primary vs 
metastatic lesions) and time (interval between biopsy and 
subsequent treatments)-dependent variability [37]. A biopsy 
sample is just a snapshot of the tumor not reflecting the 
overall tumor microenvironment. A recent study has shown 
a low intra-patient heterogeneity and temporal changes in 
PD-L1 expression using paired synchronous and 
metachronous tumor specimens of 39 NSCLC patients 
treated at Memorial Sloan Kettering Cancer Center [38] 
supporting the reliability of such biomarker for clinical use. 
In addition to such technical issue, some biological aspects 
related to the PD-L1 expression need to be also pointed out. 
Recent evidences suggested two different pathways 
modulating the PD-L1 expression on the tumor cell surface: 
the “inflammation-driven”, INF-gamma-mediated, PD-L1 
expression, which is localized at sites of inflammation and 
is usually associated with a baseline tumor T-cell infiltration; 
and the “oncogene-driven”, PD-L1 expression, which is 
constitutive, not increased by the inflammation process and 
associated with neither an immune response nor a T-cell 
tumor infiltration [39, 40]. Since several studies showed a 
significant correlation between a baseline T-cell infiltration 
in the tumor microenvironment and the clinical responses to 
immune-checkpoint inhibitors [41-43], it may be 
hypothesized that the first group of tumors, with an inflamed 
tumor microenvironment, will benefit more from anti-PD-1/
PD-L1 directed therapies, compared to those with an 
oncogene-driven PD-L1 expression status, in absence of 
T-cell infiltration in the tumor microenvironment. The 
search for predictive biomarkers needs to be implemented 
by the identification of other pathological or genomic 
determinants of response to these therapies. Some studies 
have recently demonstrated that tumor infiltrating immune 
cell IHC PD-L1 expression predict responses to 
Atezolizumab stronger than tumor PD-L1 expression [44], 
and that combining both tumor-infiltrating lymphocytes and 
IHC PD-L1 expression status, allow to identify four 
different subgroup of tumor microenvironment, which 
could benefit from different treatment strategies, including 
combination therapies [45]. Another work has shown that an 
elevated non-synonymous mutation burden, including DNA 
repair mutations, a molecular smoking signature, and a high 
neo-antigen load, are strongly associated with clinical 
activity of Pembrolizumab in NSCLC patients [46]. Some 
correlations between tumor mutation burden and PD-L1 
expression have been also found, even if it needs to be 
better explored in larger prospective studies.
Despite several limitations our pooled-analysis 
shows that tumor PD-L1 expression , IHC cut-off >1%, 
is associated with significantly higher ORRs to anti PD-1/
PD-L1 MoAbs, in pre-treated NSCLC patients. These data 
suggest that PD-L1 at the lowest expression level, though 
still limited by varied testing approaches and definitions of 
positivity, has a potential role as predictive biomarker for 
clinical setting. Probably, as suggested by recent studies, 
a combination of tumor PD-L1 expression with other 
“immune-biomarkers” will enhance our ability to identify 
not only the best candidate to receive immune-therapies, 
but also the mechanisms of immune-evasion at a single 
patient level, and ultimately personalize the immune-
treatments and combination strategies.
MATERIALS AND METHODS
Search for clinical trials
We performed our pooled-analysis according 
to a predefined written protocol. We searched for all 
published studies, that report the ORR of patients with 
NSCLC treated with anti PD1/PD-L1 MoAbs, who 
received prior chemotherapy regimens, stratified by 
tumor PD-L1 expression status (IHC cut-off point 1%). 
Publications were identified by an electronic search 
in Medline, using PubMed online service, updated in 
October 2015. The search for publications was made 
by other databases including the Cochrane Library and 
EMBASE. However the search on PubMed allowed the 
widest collection of publications about this topic. The 
following search terms were used: “PD-1”, “PD-L1”, 
“lung cancer”, “NSCLC”, “non-small cell lung cancer”, 
“predictive biomarker”, “anti-PD1”, “anti-PD-L1”, 
“monoclonal antibodies”, “cancer immunotherapy”. 
The search was limited to human studies in the English 
language. The results were supplemented with manual 
searches of American Society of Clinical Oncology 
(ASCO), European Society of Medical Oncology 
(ESMO), and World Conference of Lung Cancer 
(WCLC), meeting proceedings, references of selected 
articles and published reviews. A systematic review 
on this topic in the Cochrane database of systematic 
reviews was not found.
Selection criteria
According to this search clinical trials were 
taken into account if they had to fulfil all the following 
inclusion criteria: 1) only patients with metastatic 
NSCLC were included; 2) only patients who received 
prior therapies were included 3) studies that report the 
ORR of NSCLC patients treated with an anti-PD1/PD-
L1 MoAb as single agent; 4) studies that report the 
ORR, stratified according to the PD-L1 expression status 
(IHC cut-off point 1%).
Data extraction
Two authors independently selected studies 
according to the aforementioned inclusion criteria. If 
these two authors could not reach a consensus, another 
author was consulted and a final decision was made by 
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consensus. Information was carefully extracted by overall 
selected studies. The following data were collected and 
organized from eligible studies: first author name, journal 
and year of publication, study design, study treatment, 
baseline characteristics of patients (i.e. age, stage, PD-
L1 expression status), and ORR stratified according 
to tumor PD-L1 expression status. The proportion of 
patients for each outcome was calculated basing on 
the percentages reported in included trials, when it was 
not reported as absolute number. Data extraction was 
conducted according to the Preferred Reporting Items 
for Systematic Reviews and Meta-Analysis (PRISMA) 
guidelines [47].
Statistical analysis
Patients were stratified according to PD-L1 
expression status into 2 groups: PD-L1 positive (PD-
L1 tumor cell staining ≥1%) and PD-L1 negative. The 
outcome measure was ORR, defined as the percentage of 
patients who have a complete or partial tumor response 
according to World Health Organization (WHO) criteria or 
Response Evaluation Criteria in Solid Tumors (RECIST), 
calculated in PD-L1 positive over PD-L1 negative NSCLC 
patients. The number of events (i.e. objective responses) 
was extracted from each study or calculated from the 
percentage provided, and the proportion of patients was 
calculated for each group. The association between these 
endpoints and PD-L1 expression status was expressed as 
an odds ratio (OR) of PD-L1 positive over PD-L1 negative 
patients. Thus, an OR greater than 1 indicates that PD-
L1 overexpression (PD-L1 tumor cell staining ≥1%) 
is associated with higher ORR in pre-treated NSCLC 
patients. A pooled-analysis of ORs was performed to 
calculate a pooled OR for such outcome, using a fixed-
effect or random-effect, based on statistical significance 
of Q-test, according to Mantel-Haenszel method. 
The heterogeneity between trials was tested using the 
Cochran Q-test, with a predefined significance threshold 
of 0.1. Publication bias for ORR analysis were assessed 
using Begg’s funnel plots and Egger’s test. The level of 
significance was set at 5% (P<0.05 suggested a statistical 
significant publication bias). All statistical analyses were 
performed with Review Manager 5.3.5 (RevMan; version 
5.3.5) and Comprehensive Meta-Analysis software (CMA; 
version 3.0).
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